Why we need to separate burnout from moral injury in health care

APUGOMES/AFPviaGettyImagesInthenewbook“IfIBetrayTheseWords,”Itellthestory,withSimonTalbot,ofRitaGall Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem




knowledge

author：knowledge    Page View：988
Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

advertisement

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： With FDA staff opposed to Sarepta therapy, top official intervened
Next article： Tori Bowie and the unacceptable rates of Black maternal death